Codexis intends to prioritize advancing and commercializing its Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis platform and its Pharmaceutical Manufacturing business.
The company is discontinuing investment in certain development programs, primarily in Biotherapeutics, consolidating operations to its headquarters and reducing headcount by approximately 25%.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,